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Abstract
Overcoming pandemics, such as the current Covid-19 outbreak, requires the
manufacture of several billion doses of vaccines within months. This is an
extremely challenging task given the constraints in small-scale manufacturing
for clinical trials, clinical testing timelines involving multiple phases and large-
scale drug substance and drug product manufacturing. To tackle these chal-
lenges, regulatory processes are fast-tracked, and rapid-response manufactur-
ing platform technologies are used. Here, we evaluate the current progress,
challenges ahead and potential solutions for providing vaccines for pandemic
response at an unprecedented scale and rate. Emerging rapid-response vaccine
platform technologies, especially RNA platforms, offer a high productivity esti-
mated at over 1 billion doses per year with a small manufacturing footprint
and low capital cost facilities. The self-amplifying RNA (saRNA) drug product
cost is estimated at below 1 USD/dose. These manufacturing processes and
facilities can be decentralized to facilitate production, distribution, but also
raw material supply. The RNA platform technology can be complemented by
an a priori Quality by Design analysis aided by computational modeling in
order to assure product quality and further speed up the regulatory approval
processes when these platforms are used for epidemic or pandemic response in
the future.
KEYWORD S
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1 | INTRODUCTION
Vaccines are considered the most effective form of
healthcare intervention[1,2] and offer the promise of over-
coming the current Covid-19 pandemic caused by the
SARS-CoV-2 virus. One of the most promising technolo-
gies for the development of an effective SARS-CoV-2
vaccine are considered to be RNA and viral vector-based
platforms.[3-5] The RNA vaccine platform uses the natural
cellular protein expression pathway, based on the central
dogma of molecular biology, in which genetic informa-
tion encoded in DNA is transcribed into messenger RNA
(mRNA) and translated into protein. This way, RNA
vaccinology works by outsourcing the production of the
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vaccine protein antigen to the cells of the human body,
based on the information in the RNA sequence.[6-9] For
this, the RNA vaccine is commonly injected into the mus-
cle using predominantly a liposome-based formulation,
known as lipid nanoparticle, or a polycation-based for-
mulation.[7,9] Once inside the cells, the ribosomes pro-
duce the protein encoded by the RNA sequence, which
for the Covid-19 vaccine is the spike protein on the
SARS-CoV-2 virus surface. The produced protein antigen
(expressed as spike protein trimer) then induces the
immune response likely required to gain immunity
against the virus. There are two main types of RNA vac-
cines, mRNA[7] and self-amplifying RNA (saRNA) vac-
cines.[8,10] As their name implies, saRNA vaccines,
replicate inside cells by encoding a viral RNA replication
machinery in the saRNA strand and expressing this
inside the human cells.[8,10] This way, lower amounts of
RNA are required per vaccine dose, potentially providing
substantial cost benefits and higher productivity, in terms
of doses per liter of bioreaction, compared to non-repli-
cating mRNA vaccines.[10,11] On the other hand, mRNA
vaccines are clinically more developed and widely tested
compared to saRNA vaccines. Viral vector-based vac-
cines, such as Adenovirus vector vaccines, also utilize the
cells of the human body to synthesize the target antigen,
however they deliver a DNA payload,[12] which is first
transcribed into an mRNA and then translated into the
spike protein in the case of the Covid-19 vaccine. With
clinical trials of RNA vaccines currently ongoing, herein
we conduct a techno-economic analysis of RNA vaccine
manufacturing and present the advantages of this plat-
form with respect to development speed, manufacturing
footprint and vaccine cost.
2 | ASSESSMENT OF THE RNA
VACCINE PLATFORM
2.1 | Development timeline
Conventional vaccine development takes on average 8 to
14 years and costs 0.55 to 1 billion USD,[13-22] as illus-
trated in Figure 1. Fast-tracked regulatory processes
implemented for emergency response to pandemics can
cut the duration of pre-clinical and clinical development
to 0.8 to 1.5 years if patient recruitment and testing can
be carried out rapidly.[21,23] Emerging platform technolo-
gies, such as the RNA platform, promote pre-clinical
development at unprecedented speeds.[24,25] For example,
the Shattock group at Imperial College London generated
a prototype saRNA vaccine candidate 2 weeks after the
selection of the genetic sequence of the spike protein
from the SARS-CoV-2 virus,[3,26] and US company
Moderna, Inc. went from genetic sequence information
of the clinical material manufacturing to human testing
in only 42 days.[22] These speeds to clinical material pro-
duction provide huge advantage to clinical investigation
of multiple vaccine candidates in face of a pandemic.
During clinical development, the highest costs and lon-
gest durations are encountered in phase III clinical trials
and the highest failure rates tend to occur in phase II
clinical trials where the efficacy of the vaccines is
assessed,[14,20,27,28] cf. Figure 1A.
Once the cGMP platform production process for RNA
vaccines is developed, RNA vaccines can be produced
substantially faster compared to conventional expression
systems. For example, in the case of inactivated or live-
attenuated viral (such as the PiCoVacc SARS-CoV-2 virus
vaccine candidate being produced in Vero Cells), or
recombinant protein vaccine candidate production, prod-
uct-specific manufacturing processes have to be devel-
oped and ideally optimized, validated and approved for
cGMP production, which can take a substantial amount
of time. Additionally, the agility of the RNA platform,
which is agnostic to the disease target, means that multi-
ple iterations and vaccine variants can be rapidly pro-
duced and tested without the need for process
modification or re-validation.
The high productivity of the RNA platform as
expressed per unit volume of process and per unit time is
also considerably higher than the aforementioned con-
ventional expression systems. This makes the production
of higher volumes required for later phase trials and for
large scale production substantially easier. The time and
resource gains to be made with the RNA platform are
expected to become more apparent in the future when
this platform is fully developed and RNA vaccines gain
regulatory approval.
2.2 | Manufacturing process and
footprint
Following successful clinical trials and demonstration of
efficacy, the next challenge becomes the manufacturing
of the vaccine at the quality standards, scale and rate
required for meeting global demand. This is particularly
cumbersome in the case of pandemic-response
manufacturing, when several billion doses of vaccines
need to be manufactured within months under current
Good Manufacturing Practices (cGMP), and ideally at
low enough cost to allow affordability and mass immuni-
zation globally. Small-scale cGMP compliant RNA vac-
cine production processes have been already developed
and GMP grade RNA vaccine candidates have already
been produced for clinical trials.[29-33] In the light of the
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current COVID-19 pandemic, several companies and
consortia are scaling up RNA vaccine production to the
billion dose annual production scale.[34-39]
For rapid response manufacturing, optimal utilization
of existing facilities is crucial, however if the demand
cannot be met, the construction of additional facilities
FIGURE 1 Overview of vaccine testing and manufacturing development timelines. A, Pre-clinical development and clinical testing
timelines, costs and success/failure rates for conventional vaccines and for vaccines produced using emerging platform technologies
(eg, RNA vaccines).[13-22] Once the platform is developed and used to produce a licensed product, the costs and failure rates for developing
further products using the same platform technology would drop substantially. The highest costs and longest development timelines are
encountered in phase III clinical trials and the highest failure rates tend to occur in phase II clinical trials. B, Process development and
facility construction timelines and cost estimates for conventional and emerging platform technologies with drug substance annual
production capacities of tens to hundreds of million doses.[14,19,40-42,59] Process development and facility design is usually initiated during
pre-clinical and clinical testing and investments are usually made as failure risks reduce during clinical development. C, Comparison of
overall vaccine production rates for conventional and new platform technologies, considering the development and testing phases presented
in parts A and B above. Once fully developed and validated, the new vaccine platform technologies will produce vaccines within weeks to
months after antigen identification, which is at least 10-fold faster than conventional technologies
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will be urgently required. Crucially, manufacturing a
new vaccine of conventional format (eg, inactivated viral
vaccines) against a new disease, such as Covid-19, by re-
deploying existing large-scale facilities would also
adversely affect the supply of other medicines. With the
construction of such conventional facilities requiring
around several years and hundreds of million US dol-
lars[14,19,40-44] (Figure 1B), certain emerging platform
technologies present considerable advantages for rapid-
response manufacturing.[24]
We have built a production process model for RNA
vaccine manufacturing in SuperPro Designer (Intelligen,
Inc.) based on state-of-the-art processes, implemented in
industry for RNA synthesis utilizing DNA-templated
enzymatic RNA synthesis via the in vitro transcription
reaction catalysed by the T7 RNA polymerase
enzyme,[7,45,46] cf. the process diagram in Figure 2. The
saRNA vaccine drug substance encoding for the spike
protein from the SARS-CoV-2 has a size of around 10 k
bases (kb) and a molecular mass of around 5 Mega Dal-
ton (MDa), which is much larger when compared to the
mRNA vaccine drug substance of the same spike-
encoding protein that has a size of around 3 to 4 kb,
corresponding to 1.5 to 2 MDa.[5,47] The molecular
masses of saRNA and mRNA are an order of magnitude
larger than the T7 RNA polymerase enzyme and there-
fore size-based separation of the T7 RNA polymerase
from the RNA seems feasible. After RNA synthesis,
downstream purification can be achieved via a series of
tangential flow filtration (TFF) steps, and purities of 90%
to 99.9% and yields of 90% to 95% have been reported.[48]
TFF can also be complemented by chromatographic puri-
fication techniques, such as hydroxyapatite chromatogra-
phy, oligo(dT) chromatography, ion exchange
chromatography and core bead flow-through chromatog-
raphy (eg, Capto Core 700 beads from Cytiva, Danaher
Corporation, formerly GE Healthcare Life Sciences).[48,49]
The produced RNA drug substance is then formulated
into lipid nanoparticles[3,9,50] to complete the production
of the LNP-encapsulated/formulated RNA. The overall
LNP-encapsulation process and formulation is being
independent of the RNA sequence and, thus the targeted
disease vaccine drug product. Once the formulated RNA
is ready, it enters the fill-to-finish process where in the
required dose (plus overage) are filled into glass vials to
produce the final vaccine drug product.
Based on our techno-economic assessment, the RNA
vaccine production process can be two to three orders of
magnitude smaller than conventional vaccine production
processes in terms of facility scale, and can be con-
structed in less than half the time with 1/20 to 1/35 of
the upfront capital investment, as shown in Figure 1B. It
therefore presents a strong advantage of requiring small-
scale, high-capacity facilities, which can be constructed
more rapidly and could make wide use of single-use dis-
posable equipment. Due to its small scale, the RNA vac-
cine drug substance production process could be placed
in a small part of an existing conventional vaccine facil-
ity, for example in a room, and still produce more doses
worth of drug substance than the entire original conven-
tional vaccine production facility. To rapidly establish
such an RNA vaccine drug substance production line,
off-the-shelf single-use equipment can be used to build
the entire process. Once such a process is established and
validated based on readily available single-use equip-
ment, the technology can be transferred to other facilities
for scaling out purposes, thereby reducing process and
quality control design and development timelines and
streamlining validation and start-up activities.
Moreover, the RNA vaccine platform technology
offers the flexibility of producing a very large range of
vaccine products using the same production process,
quality control system and facility, rapidly and at high
capacity. Therefore, the production of new vaccines can
be achieved around 10× faster compared to conventional
vaccine production technologies, as shown in Figure 1C.
In such a scenario, the cost of an RNA vaccine drug sub-
stance manufacturing facility, besides scale also depends
on the grade of the clean rooms or required containment
level. If the RNA production can take place in a closed
system,[48] then lower grade facilities and rooms can even
be used, which would cost substantially less to construct,
operate and maintain compared to high grade clean room
containing facilities, of course, following the appropriate
regulatory and compliance guidelines.[49]
2.3 | Process performance and costs
Based on our process-cost modeling in SuperPro Designer
(the model, relevant assumptions and simulation results
report are available on GitHub at https://github.com/
ZKis-ZK/RNA-vaccine-drug-substance-production-
techno-economic-modelling), the saRNA platform can
produce over 1 billion vaccine doses worth of drug sub-
stance per year at a small process scale corresponding to
5 L bioreactor working volume in a correspondingly
small facility footprint that would cost around 20 million
USD to construct, equip, validate and start up. The
annual operating costs are estimated to be over 100 mil-
lion USD due to the high cost of raw materials involved
in RNA synthesis and LNP production. This 100 million
USD/year estimate includes material and consumable
costs, labor costs, facility-dependent costs, quality control
and quality assurance costs, and waste disposal costs. Out
of these, the 50 cap analogue raw material is the major
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FIGURE 2 Process flow diagram for saRNA vaccine production based on the in vitro transcription enzymatic reaction. In the upstream
process the DNA template is generated, amplified, purified and linearized. In the mid-stream process the RNA is synthesized following the
in vitro transcription reaction using the T7 RNA polymerase enzyme, and 50 capping of the RNA is achieved co-transcriptionally using 50 cap
analogues (needed to ensure antigen expression). For downstream purification TFF can be used also in combination with chromatography
methods, such as hydroxyapatite chromatography and core bead flow-through chromatography. In the first TFF step the saRNA and
linearized DNA template are retained by the filter and smaller molecular size components, including the T7 RNA polymerase enzyme, flow
through the filter. Next, the linearized DNA template is digested using nucleases and then the DNA nucleotides can be separated from the
RNA using another TFF step. The obtained drug substance is then formulated predominantly in lipid nanoparticles, however polycationic
formulations are also developed and evaluated. Next, the formulated saRNA undergoes quality control and is filled into vials or containers
for pandemic-scale mass vaccination. The vials are then capped, sealed, inspected using automated image processing, labeled and packaged
into secondary and tertiary packaging. The entire production process is independent of the RNA sequence, therefore in principle vaccines
against virtually any disease can be produced using the same production process[24,46,48,49,60]
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cost component, accounting for over 50% of the total
operating costs. The highest-efficiency 50 cap analogues
are CleanCap AG and CleanCapAU (TriLink Biotechnol-
ogies, Inc.) for mRNA and saRNA vaccines, respec-
tively.[51] The 50 cap structure is crucial for avoiding
degradation of the RNA by the innate immune mecha-
nisms, which associate non-capped RNA with foreign
(eg, viral) material and ensures protein antigen expres-
sion from the RNA polymer.[52] The production of 50 cap
analogues is currently being scaled up to ensure availabil-
ity for billion-dose scale RNA vaccine production.[53] We
therefore do not envisage the availability of 50 cap ana-
logues to be a bottleneck, particularly for saRNA produc-
tion, although raw material shortages cannot be ruled
out during pandemic-response mass vaccine
manufacture.
The amount of RNA drug substance per dose is esti-
mated to be in the range of 0.1 to 10 μg/dose[3,10,11] and
25 to 250 μg/dose[3,54] for saRNA and mRNA vaccines,
respectively. The actual amount will be determined dur-
ing clinical trials. Given this difference and range in the
amount of RNA drug substance per dose, the price per
dose, production amounts and production rates will vary
accordingly. This is in line with the original intended
purpose of these vaccines: mRNA vaccines were origi-
nally developed as anti-cancer vaccines without prioritiz-
ing ultra-low cost per dose.[5,6,10] On the other hand,
saRNA vaccines have been developed for infectious dis-
eases and rapid pandemic response, considering the pur-
chasing power of developing countries and thus aiming
to minimize cost per dose.[5,6,10] Based on our cost model-
ing, a cost per dose of below 1 USD/dose, including
options for fill-to-finish into multidose vials, appears
achievable for saRNA vaccines. This cost could be well
above 1 USD/dose for mRNA vaccines. The drug
substance cost per dose and productivity, in terms of
doses worth of drug substance produced per unit time,
has a linear dependence on the drug substance amount
per dose. This way, the drug substance cost per dose can
decrease and productivity can increase by two orders of
magnitude in case of moving from 10 to 0.1 μg/dose for
saRNA vaccines. As listed in Table 1, besides the RNA
amount per dose, the cost per dose and production pro-
cess performance for both mRNA and saRNA vaccines
will depend on the process scale, production titre, cost of
the 50 cap analogue or the 50 capping approach used (co-
transcriptional vs enzymatic post-transcriptional),[7] effi-
ciency and cost of downstream purification methods, the
facility-related costs and the possibility of recycling high
value materials for producing a subsequent batch of the
same product. The time required to produce a batch of
RNA drug substance is around 11 hours, if production
batches are scheduled such that the end of a batch over-
laps with the beginning of the subsequent batch in order
to increase the utilization of the production line. Contin-
uous RNA synthesis production processes whereby the
RNA product is continuously exiting the bioreactor and
the high value raw materials are kept in the bioreactor
also offer a substantial material cost reduction poten-
tial.[55] Besides the manufacturing costs, the final sale
price of the vaccine is also expected to include R&D costs,
costs of clinical trials, marketing and supply chain costs
and a profit margin.
3 | CHALLENGES AHEAD AND
POTENTIAL SOLUTIONS
The biggest challenge for saRNA and mRNA vaccines
currently is to demonstrate efficacy against target disease
TABLE 1 Parameters influencing RNA vaccine production performance and cost
Parameter Range Unit Influencing and determining factors Reference
RNA amount per dose 0.1-10 for saRNA
25-250 for mRNA
μg/dose Clinical trials 3,10,11,54 α
Process scale 0.5-50 L Demand, scale-up optimization 46,49,55,60
Production titres 1.5-7 g/L Reaction optimization, process development 46,55
50 Cap analogue cost 2500-10 000 USD/g Scale and supplier purchase price 53
Downstream purification losses 20-50 % Type of unit operations, process development 48,49,60 β
Raw material recyclinga 0-8 Fold Stability of the materials, regulatory approval α
Capital investment costs 10-40 Million USD Production scale, grade and containment
level of the facility
β
Vial or container cost 0.1-0.6 USD/dose Number of doses per container or vial 56,61
Note: α—Assumed by the authors; β—calculated using SuperPro Designer V10 (Intelligen, Inc.).
aRecycling or re-use of the materials for producing multiple batches of the same product. For this, high cost raw material (eg, the 50 cap ana-
logue and enzymes) can be separated from the RNA product using TFF and fed back into the RNA synthesis bioreactor.
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in clinical trials, especially the Phase II/III efficacy trials,
where the highest proportion of vaccines tend to fail.
However, the success rate during clinical trials can be
increased and the clinical development timelines can in
principle be reduced, because the generic feature of the
RNA platform allows for the rapid production and devel-
opment of many vaccine variants, allowing for rapid iter-
ations during clinical development. Additionally, there
are numerous intellectual property challenges to be
solved, including the ones related to LNP-based formula-
tion. However, it seems that there are no technical or
scalability bottleneck related to current formulation pro-
cesses when considering high-volume pandemic-response
production. On the other hand, formulation raw material
availability can become a bottleneck during high-volume
pandemic-response vaccine production, however, their
production is also being scaled up to meet global
demand. Pandemic-induced transportation disruptions
can limit the availability of raw materials, impacting spe-
cialty materials more substantially due to the lower num-
ber of suppliers. To mitigate this, distributed or
outsourced manufacturing of raw materials across several
continents could offer a solution. The stability of the vac-
cine can also influence its global distribution and avail-
ability. This way, vaccines which are stable and require
distribution at −70C, would limit distribution in low
and middle income countries due to the lack of the
appropriate cold chain infrastructure, would limit the use
of multidose vials, and would increase the cost per dose
due to cold chain distribution costs and because of the
single dose vial (or low dose number) format. To over-
come this issue, vaccine developers are evaluating formu-
lations with higher thermostability or lyophilized
formulations.
Finally, there is a need for additional manufacturing
capacity for pandemic-response production. However,
the RNA vaccine production processes are extremely
productive, especially for saRNA vaccines due to lower
expected amount per dose. With the annual production
of saRNA drug substance for over 1 billion doses using
a 5 L bioreactor working volume, the bottleneck is
expected to be the fill-to-finish process that may not be
able to fill billions of vials with formulated RNA, at
room temperature, particularly when the formulated
RNA may not be stable at that condition for a pro-
longed period of time. To address this, 200 dose bags
are being evaluated by CEPI, which can be filled at a
rate of 3 million vaccine doses during an 8 to 10 hours
manufacturing work shift.[56,57] This will potentially add
complexity to the final vaccine administration step in
clinic where the pharmacists and medical professionals
will need familiarity with the new requirements of this
technology.
Once the saRNA and mRNA platforms are fully
developed, stability issues resolved, manufacturing and
operational processes addressed and pandemic-ready, the
regulatory processes could, in principle, be accelerated to
rapidly respond to future epidemics and pandemics by
applying a Quality by Design (QbD) framework aided by
FIGURE 3 Quality-by-design (QbD) framework. The QbD
development cycle begins with identifying the patient needs and
based on these the Quality Target Product Profile (QTPP) is
defined. From the QTPP, the critical quality attributes (CQAs) of
the product and their ranges are determined using a risk
assessment scoring, based on clinical and non-clinical data, for both
safety and efficacy. Next, based on the CQAs and on understanding
the of production process, the critical process parameter (CPP)
ranges are defined. Mathematical relations between CPPs and
CQAs are established, obtaining this way a mathematical model of
the vaccine production process. Using this model, the ranges of
CPPs which yield the desired CQAs are determined. Based on these
CPP ranges, the design space is determined and therein a sub-space
called the normal operating range (NOR) is defined. The NOR
offers the flexibility of modifying operating parameters in the GMP
production process, thus allowing optimization to account for
inherent biological heterogeneity, instead of “freezing” the GMP
process. The QbD bioprocess model can be adapted for advanced
process control, using model predictive control and real-time
measurement data from the production process. Such a “digital
twin” model can predict CQA values in the following time window
(eg, next 5 minutes) and if CQAs are predicted violate the specified
ranges, the model can recommend corrective measures, that is,
control actions, to prevent CQAs going out of the specified ranges,
fixing mistakes before these occur. Thus, computational modeling
tools can be integrated with experimental development and QbD
follows an iterative development cycle to ensure continuous
improvement through the product-process life cycle[58]
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computational modeling, cf. Figure 3. QbD is a system-
atic approach to pharmaceutical product development
that begins with pre-defined objectives and integrates
product and process understanding, identification of criti-
cal quality attributes (CQAs) and critical process parame-
ters (CPPs), product quality risk management and
development of robust control strategy to ensure the
quality of the product.[58] For accelerated development,
this framework would incorporate bioprocess modeling,
soft sensing and advanced process control in order to
consistently ensure the quality of the manufactured drug
substance and drug product. The RNA platform technolo-
gies can be supplemented with the above mentioned
QbD framework, which could be applied universally and
a priori to assure the quality and speed during develop-
ment of any RNA vaccine production process, indepen-
dently of the RNA sequence and disease target.
To develop such a QbD framework, the iterative cycle
described in Figure 3 can be employed. For this the Qual-
ity Target Product Profile (QTPP) can be determined
based on the optimal profile of the vaccine to meet
patient needs and provide highest level of protection.
Then the critical quality attributes (CQAs) of the product
and their ranges can be determined based on the QTPP,
by using a risk assessment scoring. Next, critical process
parameter (CPP) ranges can be defined based on the
CQAs and on the understanding of the production pro-
cess. Next mathematical relations between CPPs and
CQAs can be established, thereby obtaining a mathemati-
cal model of the vaccine production process. This model
can be data-driven, statistical, mechanistic or hybrid and,
in all cases, it can be further calibrated and then vali-
dated with experimental data. Mechanistic models or
mechanistic components of a hybrid model usually tend
to provide more predictive power than data-driven math-
ematical descriptions. By running the validated mathe-
matical model, the ranges of CPPs which yield the
desired CQAs can be determined and, based on these, the
design space can be established. Within the design space,
a sub-space, called the normal operating range (NOR),
can be defined that offers the flexibility of modifying and
optimizing operating parameters in the GMP production
process, rather than “freezing” the cGMP process. The
model can be simplified and adapted for advanced auto-
mation, based on model predictive control, which uses
real-time data from the production processes. By cou-
pling such a modeling-aided QbD framework to the
saRNA or mRNA platforms, the quality aspects of RNA-
product can be harmonized, and regulatory processes
could, in principle, be accelerated. In addition, this
modeling-aided QbD framework can also ensure better
management of product quality risks during scale-up and
subsequent manufacturing.
During a pandemic, manufacturing and supply chain
challenges can occur due to lockdowns, closures of
upstream manufacturing facilities (eg, raw material, con-
sumable and single-use equipment manufacturing),
reduction of labor force due to health issues caused by
the outbreak, travel and transportation restrictions and
due to contamination risks of input materials. These
threats can cause more severe sourcing disruptions in
case of centralized manufacturing and supply chains, due
to the reliance on a small number of key manufacturing
facilities and supply chain routes. This can be partially
addressed by maintaining adequate stock levels and more
appropriately addressed by the implementation of distrib-
uted, that is, decentralized, manufacturing and supply
chains. This way, the number of facilities and supply
routes could increase, therefore reducing the risk of lack
of raw materials and consumables at a single location
(although we note that the decentralized system creates
more complex inbound material supply chains), and ulti-
mately increasing the probability of the sustained vaccine
supply.
4 | CONCLUSIONS
To address pandemics, such as the Covid-19, several bil-
lion doses of vaccines are needed within months. Emerg-
ing outbreak-response platform technologies, especially
the RNA platform, appear capable of addressing this
extremely challenging task, due to their high productivity
at low manufacturing footprint and its ability to” release”
millions of doses through rapid quality control testing.
Specifically, a facility with a single 5 L bioreactor work-
ing volume can be sufficient to produce an estimated 1
billion vaccine doses per year at a drug product cost of
below 1 USD/dose. This further increases the possibility
of distributed manufacturing and thus contributing to
vaccine supply sustainability. Given that RNA vaccine
production processes are two to three orders of magni-
tude smaller than conventional vaccine production pro-
cesses, they can be built in less than half the time with 1/
20 to 1/35 of the upfront capital costs compared to con-
ventional vaccine production processes. Inclusion of sin-
gle-use technologies in RNA vaccine manufacturing can
further accelerate this timeline. Once the RNA produc-
tion platform is established, the overall clinical develop-
ment process could, in principle, be further accelerated
by the utilization of a computational model-aided QbD
platform, which would complement the platform produc-
tion, independent of the RNA sequence. This would
enable the development of a platform process agnostic to
the infectious disease target, which can be rapidly
deployed to both develop candidate vaccines for testing
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and large-scale manufacture. Despite the numerous pro-
duction and affordability advantages, the RNA platform
still remains unproven with no commercial vaccine
developed using this “disruptive” technology. As multiple
organizations exploit this technology to develop vaccines
against SARS-CoV-2, the benefits and practical limita-
tions of this technology will be tested, providing lessons
for further iteration and improvements.
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